Steve W. Kerrigan

Professor Steven W. Kerrigan is deputy head of the School of Pharmacy (Research), head of the Cardiovascular Infection Research Group at the Royal College of Surgeons in Ireland (RCSI), University of Medicine and Health Sciences, and inventor of the sepsis treatment drug InnovoSep. Professor Kerrigan is a graduate of King’s College London, England (Pharmacology), University of Strathclyde, Scotland (Immunopharmacology), and RCSI (Infection and Immunity). His research focuses on understanding the platelet and endothelial response to infection during sepsis. Through research, Professor Kerrigan identified a promising drug target that prevents a wide number of microorganisms (bacteria, fungus, and virus) from causing a dysregulated response in the systemic circulation during sepsis, specifically preventing unwanted platelet and endothelial cell activation. Professor Kerrigan has published extensively in leading high-impact journals in the areas of platelets, endothelial cells, and bloodstream infections, and has attracted more than €6.5 million in grant funding and filed three patent/disclosures. Professor Kerrigan is currently co-chair of the ISTH Scientific Standardization Committee Biorheology (platelets) and member of the European Sepsis Alliance research committee.